Both NIV and HFNC are used to treat patients with acute respiratory failure. Current guidelines recommend NIV for acute respiratory failure caused by COPD and acute cardiogenic pulmonary edema. However, NIV may be hard for some patients to tolerate. When compared to low-flow oxygen therapy, HFNC has been shown to improve oxygenation, improve alveolar recruitment, and enhance clearance of secretions. HFNC may be easier to use and tolerate than NIV, but there remains uncertainty regarding the effectiveness of HFNC compared to NIV for acute hypoxemic respiratory failure. In this podcast, we discuss the RENOVATE trial that sought to compare HFNC with NIV on rates of intubation in patients with acute respiratory failure.
There has been an explosion of literature on the evaluation and management of patients with COVID-19 infection. In this podcast, we discuss updates (as...
In recent years, numerous trials have investigated the administration of corticosteroids in patients with pneumonia and have produced mixed results. In this podcast, we...
In this podcast, we discuss the recently published ADRENAL study and its implications for the use of steroids for patients with refractory septic shock?...